Clinical Trials Logo

Carcinoid Syndrome clinical trials

View clinical trials related to Carcinoid Syndrome.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05756608 Recruiting - Aortic Stenosis Clinical Trials

Fibrosis in Chronic and Delayed Myocardial Infarction

FCDMI
Start date: November 10, 2022
Phase:
Study type: Observational

In this study the investigators aim to examine the role that fibrosis plays in heart conditions such as aortic stenosis , chemotherapy-induced cardiotoxicity and carcinoid syndrome . Fibrosis is a common final result following any injury to the heart muscle and the investigators aim to identify this process early and in its active state. This will be examined by using a radiotracer 68Ga-FAPI or 18F-AlF-FAPI and PET-MRI or PET-CT.

NCT ID: NCT04993261 Recruiting - Carcinoid Tumor Clinical Trials

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Start date: September 23, 2015
Phase: Early Phase 1
Study type: Interventional

This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and a computer to create images of areas inside the body. Dual energy computed tomography is a technique used during routine CT scans to help obtain and process the image after the scan is complete. Doctors want to learn if dual energy computed tomography can help improve the detection of carcinoid tumors during routine CT scans.

NCT ID: NCT03453489 Recruiting - Carcinoid Syndrome Clinical Trials

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

Start date: June 20, 2018
Phase: Phase 2
Study type: Interventional

This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11 alpha-methyltryptophan (AMT)-emission tomography (PET). Telotristat etiprate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying the changes within the tumor cells via AMT-PET may help doctors better understand how tumors respond to treatment with telotristat etiprate.